- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04735744
Evaluation of Allied Healthcare in Patients Recovering From COVID-19 (ParaCOV)
SUMMARY Rationale: Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) might play an important role in the recovery of patients with COVID-19 who experience limitations in daily physical functioning and participation. However, the evidence base for allied healthcare in patients with COVID-19 has yet to be established. To facilitate care for people recovering from COVID-19 and to establish this evidence base, the Dutch ministry has created a temporary regulation for primary care allied healthcare specifically for patients with COVID-19.
Objective: This study is setup alongside the temporary regulation and aims to evaluate the longitudinal recovery trajectories and related costs of patients who visited a primary care allied healthcare professional for the management of severe symptoms and activity limitations and/or participation restrictions related to COVID-19.
Study design: Prospective cohort study. Study population: 1,315 adult patients recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, and who are referred to a primary care allied health professional by a general practitioner or medical specialist within four months of the start of the disease will be eligible for this study.
Intervention (if applicable): Although the nature of this study is non-experimental, the allied healthcare intervention can be considered experimental due to the novelty of the disease.
Main study parameters/endpoints: The primary outcome domain of this study is participation measured with the Utrechtse Schaal voor Revalidatie - Participatie (USER-P). The primary endpoint is set at 6 months. A 5 point difference will be considered clinically relevant for patients with COVID-19.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: There are no specific risks involved with participation in this study, as it entails the completion of questionnaires over the timeframe of one year (at the start of the treatment, the end of the treatment, 3 months, 6 months, 9 months and 12 months). The load of the survey will be highest at months 3, 6 and 12 with a total of 74 survey items. Input from patient representatives suggested that this number of items was feasible, especially because participants are allowed to complete the survey over a number of days. Finally, none of the items in the survey are considered emotionally distressing. The prescribed interventions are conform the recommendations of the best available evidence and are in line with usual allied healthcare interventions. Therefore, risks are likely to be negligible conform usual allied healthcare.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
Gelderland
-
Nijmegen, Gelderland, Netherlands, 6500HB
- Radboud University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Adult patients of 18 year and older recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, who are referred to a primary care allied health professional* by a general practitioner or medical specialist are deemed eligible for this study.
*Allied health professionals relevant to this study are: Dietitians, Exercise Therapists, Occupational Therapists, Physical Therapists, and Speech and Language Therapists working in primary care in the Netherlands.
Description
Inclusion Criteria:
Adult patients
- recovering from COVID-19 with severe symptoms and activity limitations and/or participation restrictions, and;
- who are referred to a primary care allied health professional by a general practitioner or medical specialist within four months of the start of the disease; will be eligible for this study. The need for referring the patient to an allied health professional will be judged by the primary care physician or medical specialist. Criteria for referral are described in guidance published by the Long Alliantie Nederland (LAN) with recommendations for treatment of post-COVID-19-patients: the COVID-19 Associated Syndrome (CAS) (Chapters 3.3 and 4).
http://www.longalliantie.nl/files/2515/9359/4621/Handreiking_voor_de_zorg.pdf
Exclusion Criteria:
Adult patients:
- receiving palliative care; are excluded from this study.
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Prospective cohort
Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that treat patients recovering from COVID-19 in Dutch primary care
|
We will not develop specific interventions for this prospective observational cohort study.
The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN.
All allied health professionals are working according to these recommendations.
Dissemination of these recommendations is done by the professional bodies of the allied health professionals.
Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
|
|
Retrospective cohort
Allied health professionals (i.e., dietitians, exercise therapists, physical therapists, occupational therapists and speech and language therapists) that have been treated patients recovering from COVID-19 in Dutch primary care
|
We will not develop specific interventions for this prospective observational cohort study.
The care provided by allied health professionals in daily practice are based on recommendations published by the professional bodies of allied health professionals and on the interdisciplinary guidance developed by the LAN.
All allied health professionals are working according to these recommendations.
Dissemination of these recommendations is done by the professional bodies of the allied health professionals.
Given the observational nature of our study, no additional implementation strategies will be employed to stimulate this care by the research group.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Participation
Time Frame: Baseline (T0)
|
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
|
Baseline (T0)
|
|
Participation
Time Frame: 3 months (T1)
|
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
|
3 months (T1)
|
|
Participation
Time Frame: 6 months (T2)
|
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
|
6 months (T2)
|
|
Participation
Time Frame: 12 months (T3)
|
Measured with the Utrecht Scale for Evaluation of Rehabilitation Participation (USER-P) (32 items)
|
12 months (T3)
|
|
Quality of life measured with EQ-5D-5L
Time Frame: Baseline (T0)
|
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
|
Baseline (T0)
|
|
Quality of life measured with EQ-5D-5L
Time Frame: 3 months (T1)
|
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
|
3 months (T1)
|
|
Quality of life measured with EQ-5D-5L
Time Frame: 6 months (T2)
|
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
|
6 months (T2)
|
|
Quality of life measured with EQ-5D-5L
Time Frame: 12 months (T3)
|
Measured with the EuroQol five-dimensional questionnaire (EQ-5D-5L) (5 items)
|
12 months (T3)
|
|
Fatigue
Time Frame: Baseline (T0)
|
Measured with the Fatigue Severity Scale (FSS)
|
Baseline (T0)
|
|
Fatigue
Time Frame: 3 months (T1)
|
Measured with the Fatigue Severity Scale (FSS)
|
3 months (T1)
|
|
Fatigue
Time Frame: 6 months (T2)
|
Measured with the Fatigue Severity Scale (FSS)
|
6 months (T2)
|
|
Fatigue
Time Frame: 12 months (T3)
|
Measured with the Fatigue Severity Scale (FSS)
|
12 months (T3)
|
|
Physical functioning
Time Frame: Baseline (T0)
|
PROMIS Physical Functioning Short Form 10b (10 items).
|
Baseline (T0)
|
|
Physical functioning
Time Frame: 3 months (T1)
|
PROMIS Physical Functioning Short Form 10b (10 items).
|
3 months (T1)
|
|
Physical functioning
Time Frame: 6 months (T2)
|
PROMIS Physical Functioning Short Form 10b (10 items).
|
6 months (T2)
|
|
Physical functioning
Time Frame: 12 months (T3)
|
PROMIS Physical Functioning Short Form 10b (10 items).
|
12 months (T3)
|
|
Costs
Time Frame: Baseline (T0)
|
will be measured using a cost questionnaire (18 items)
|
Baseline (T0)
|
|
Costs
Time Frame: 3 months (T1)
|
will be measured using a cost questionnaire (18 items)
|
3 months (T1)
|
|
Costs
Time Frame: 6 months (T2)
|
will be measured using a cost questionnaire (18 items)
|
6 months (T2)
|
|
Costs
Time Frame: 9 months (T3)
|
will be measured using a cost questionnaire (18 items)
|
9 months (T3)
|
|
Costs
Time Frame: 12 months (T4)
|
will be measured using a cost questionnaire (18 items)
|
12 months (T4)
|
|
Patient Specific Activities
Time Frame: baseline (T0) as part of usual care
|
measured with the Patient Specific Complaints (PSC)
|
baseline (T0) as part of usual care
|
|
Patient Specific Activities
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with the Patient Specific Complaints (PSC)
|
end of the treatment as part of usual care (average of 6 months)
|
|
Nutritional Status
Time Frame: baseline (T0) as part of usual care
|
measured with the BMI (weight and height)
|
baseline (T0) as part of usual care
|
|
Nutritional Status
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with the BMI (weight and height)
|
end of the treatment as part of usual care (average of 6 months)
|
|
Global Assessment
Time Frame: baseline (T0) as part of usual care
|
measured with the PG-SGA short form weight history, food intake, symptoms, activities and function).
|
baseline (T0) as part of usual care
|
|
Global Assessment
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with the PG-SGA short form weight history, food intake, symptoms, activities and function).
|
end of the treatment as part of usual care (average of 6 months)
|
|
Voice Problems
Time Frame: baseline (T0) as part of usual care
|
measured with Voice Handicap Index (VHI)
|
baseline (T0) as part of usual care
|
|
Voice Problems
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with Voice Handicap Index (VHI)
|
end of the treatment as part of usual care (average of 6 months)
|
|
Swallowing Problems
Time Frame: baseline (T0) as part of usual care
|
Dysphagia Handicap Index (DHI).
|
baseline (T0) as part of usual care
|
|
Swallowing Problems
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
Dysphagia Handicap Index (DHI).
|
end of the treatment as part of usual care (average of 6 months)
|
|
Patient Specific Activities
Time Frame: baseline (T0) as part of usual care
|
measured with the Canadian Occupational Performance Measure (COPM)
|
baseline (T0) as part of usual care
|
|
Patient Specific Activities
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with the Canadian Occupational Performance Measure (COPM)
|
end of the treatment as part of usual care (average of 6 months)
|
|
Activities
Time Frame: baseline (T0) as part of usual care
|
measured with the PRO-ergo
|
baseline (T0) as part of usual care
|
|
Activities
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with the PRO-ergo
|
end of the treatment as part of usual care (average of 6 months)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Exercise capacity
Time Frame: baseline (T0) as part of usual care
|
6 Minute Walk Test (6MWT)
|
baseline (T0) as part of usual care
|
|
Exercise capacity
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
6 Minute Walk Test (6MWT)
|
end of the treatment as part of usual care (average of 6 months)
|
|
Exercise capacity
Time Frame: baseline (T0) as part of usual care
|
Short Physical Performance Battery (SPPB)
|
baseline (T0) as part of usual care
|
|
Exercise capacity
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
Short Physical Performance Battery (SPPB)
|
end of the treatment as part of usual care (average of 6 months)
|
|
Quadriceps strength
Time Frame: baseline (T0) as part of usual care
|
with a hand dynamometer.
|
baseline (T0) as part of usual care
|
|
Quadriceps strength
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
with a hand dynamometer.
|
end of the treatment as part of usual care (average of 6 months)
|
|
Hand grip strength
Time Frame: baseline (T0) as part of usual care
|
with a hand dynamometer.
|
baseline (T0) as part of usual care
|
|
Hand grip strength
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
with a hand dynamometer.
|
end of the treatment as part of usual care (average of 6 months)
|
|
Bioimpedance (BIA
Time Frame: baseline (T0) as part of usual care
|
baseline (T0) as part of usual care
|
|
|
Bioimpedance (BIA
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
end of the treatment as part of usual care (average of 6 months)
|
|
|
VAS-appetite, taste and smell
Time Frame: baseline (T0) as part of usual care
|
baseline (T0) as part of usual care
|
|
|
VAS-appetite, taste and smell
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
end of the treatment as part of usual care (average of 6 months)
|
|
|
Dietary goal attainment
Time Frame: baseline (T0) as part of usual care
|
baseline (T0) as part of usual care
|
|
|
Dietary goal attainment
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
end of the treatment as part of usual care (average of 6 months)
|
|
|
Liquid medical nutrition
Time Frame: baseline (T0) as part of usual care
|
baseline (T0) as part of usual care
|
|
|
Liquid medical nutrition
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
end of the treatment as part of usual care (average of 6 months)
|
|
|
Sarcopenia
Time Frame: baseline (T0) as part of usual care
|
measured with the SARC-F
|
baseline (T0) as part of usual care
|
|
Sarcopenia
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with the SARC-F
|
end of the treatment as part of usual care (average of 6 months)
|
|
Types of Stool
Time Frame: baseline (T0) as part of usual care
|
measured with the Bristol Stool Chart (BCS)
|
baseline (T0) as part of usual care
|
|
Types of Stool
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with the Bristol Stool Chart (BCS)
|
end of the treatment as part of usual care (average of 6 months)
|
|
Voice Problems
Time Frame: baseline (T0) as part of usual care
|
measured with Maximum Phonation Time (MPT)
|
baseline (T0) as part of usual care
|
|
Voice Problems
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with Maximum Phonation Time (MPT)
|
end of the treatment as part of usual care (average of 6 months)
|
|
Swallowing Problems
Time Frame: baseline (T0) as part of usual care
|
measured with Maximum Swallowing Speed (MSP)
|
baseline (T0) as part of usual care
|
|
Swallowing Problems
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with Maximum Swallowing Speed (MSP)
|
end of the treatment as part of usual care (average of 6 months)
|
|
Physical Functioning
Time Frame: baseline (T0) as part of usual care
|
measured with the Assessment of Motor and Process Skills (AMPS)
|
baseline (T0) as part of usual care
|
|
Physical Functioning
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with the Assessment of Motor and Process Skills (AMPS)
|
end of the treatment as part of usual care (average of 6 months)
|
|
Cognitive Functioning
Time Frame: baseline (T0) as part of usual care
|
measured with the Cognitive Complaints - Participation (CoCo-P)
|
baseline (T0) as part of usual care
|
|
Cognitive Functioning
Time Frame: end of the treatment as part of usual care (average of 6 months)
|
measured with the Cognitive Complaints - Participation (CoCo-P)
|
end of the treatment as part of usual care (average of 6 months)
|
Collaborators and Investigators
Investigators
- Principal Investigator: Philip van der Wees, Prof. dr., Radboud University Medical Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ParaCOV
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Covid19
-
Anavasi DiagnosticsNot yet recruiting
-
Ain Shams UniversityRecruiting
-
Israel Institute for Biological Research (IIBR)Completed
-
Colgate PalmoliveCompleted
-
Christian von BuchwaldCompleted
-
Luye Pharma Group Ltd.Shandong Boan Biotechnology Co., LtdActive, not recruiting
-
University of ZurichLabor Speiz; Swiss Armed Forces; Universitatsspital ZurichEnrolling by invitation
-
Alexandria UniversityCompleted
-
Erasmus Medical CenterUniversity Medical Center Groningen; Academisch Medisch Centrum - Universiteit... and other collaboratorsRecruiting
Clinical Trials on Patients recovering from COVID19 receive usual care by allied health professionals
-
Memorial Sloan Kettering Cancer CenterCompletedAcute Myeloid Leukemia | Advanced Myelodysplastic SyndromesUnited States